drugset / Trial / NCT00682929
Cannabis for Spasticity in Multiple Sclerosis
Phase 1/2
Terminated
41 enrolled
University of California, Davis
National Multiple Sclerosis Society · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sclerosis.
Timeline
- Start
- 2004-04-14
- Primary completion
- 2011-08-17
- Completion
- 2011-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cannabis | Traditional medicine (herbal / TCM) | — | Inhaled |
| Comparator | Dronabinol | Other / unclassified | 10 mg | Oral |